Abstract: The present invention relates to the fields of medicinal chemistry and medicine, and in particular to quinolin-2-yl nitrones with the formula I as pharmaceutically active compounds. These compounds can be used as drugs for the treatment of neurodegenerative diseases by inhibiting BChE or MAO-B, either alone or in combination with other beneficial activities, such as antioxidant properties and metal chelation.

Abstract: The present invention refers to steroidal nitrone (E)-N-((8S,9S,10R,13R,14S,17R)-10,13-di methyl-17-(R)-6-methyl hepta n-2-yl)-7,8,9,11,12,13,14,15,16,17-deca hydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide (F2), as well as any pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of permanent cerebral ischemia.

Abstract: The invention relates to neuroprotective, antioxidant quinolylnitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer's and Parkinson's disease and amyotrophic lateral sclerosis.

Abstract: The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis.

Abstract: The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis.

Abstract: The present invention relates to a compound of formula (I): wherein: R1 and R2 are selected from among H and C1-C10 alkyl; R3 is selected from among H, —OR4, N, —CN, —C(O)R4, —C(O)OR4, —C(O)NR4R5, —C?NR4, —OC(O)R4, —NR4R5, —NR4C(O)R5, —NO2, —N?CR4R5, halogen and C1-C10 alkyl, wherein R4 and R5 are selected from among H, alkyl, alkenyl, cycloalkyl and aryl; X, Y, Z1, Z2 and Z3 are selected independently from among CH and N; A is selected from among (CH2)n, NH, O and CO, wherein n is an integer between 1 and 6, to the procedure for the obtainment of said compounds, to a pharmaceutical composition comprising said compound, and to the use thereof in the treatment of a neurodegenerative disease, more particularly treatment of Alzheimer's or Parkinson's disease.

Abstract: The present invention relates to a compound of formula (I) wherein: R1 and R2 are selected from among H and C1-C10 alkyl; R3 is selected from among H, —OR4, N, —CN, —C(O)R4, —C(O)OR4, —C(O)N4R5, —C?NR4, —OC(O)R4, —NR4R5, —NR4C(O)R5, —NO2, —N?CR4R5, halogen and C1-C10 alkyl, wherein R4 and R5 are selected from among H, alkyl, alkenyl, cycloalkyl and aryl; X, Y, Z1, Z2 and Z3 are selected independently from among CH and N; A is selected from among (CH2)n, NH, O and CO, wherein n is an integer between 1 and 6, to the procedure for the obtainment of said compounds, to a pharmaceutical composition comprising said compound, and to the use thereof in the treatment of a neurodegenerative disease, more particularly treatment of Alzheimer's or Parkinson's disease.